MarketCap
Eli Lilly and Company LLY
$ 1 277.31
-0.56%
Facebook
X
Telegram
Eli Lilly and Company ROE Ratio | LLY
Annual ROE Ratio Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.78 | 74.2 | 48.65 | 58.64 | 62.16 | 109.79 | 308.19 | 29.63 | -1.75 | 19.44 | 16.51 | 15.53 | 26.56 | 27.67 | 32.12 | 40.82 | 45.45 | -30.75 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 308.19 | -30.75 | 53.37 |
Quarterly ROE Ratio Eli Lilly and Company
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 99.09 | 95.65 | 78.76 | 77.17 | 63.7 | 45.69 | 54.81 | 44.95 | 41.86 | 62.76 | 61.14 | 49.12 | 70.69 | 56.28 | 75.92 | 55.53 | 76.95 | 87.67 | 91.91 | 72.26 | 129.64 | 156.32 | 182.2 | 319.09 | 273.16 | 236.76 | 183.2 | 32.88 | 7.14 | 0.24 | 11.58 | -1.76 | 18.04 | 18.8 | 15.45 | 19.54 | 17.32 | 17.25 | 16.04 | 16.53 | 16.03 | 13.8 | 14.45 | 15.55 | 16.89 | 20.46 | 22.53 | 26.57 | 28.05 | 30.2 | 29.61 | 27.68 | 31.21 | 31.07 | 32.62 | 25.78 | 36.28 | 40.33 | 43.41 | 45.12 | 48.15 | 11.93 | 9.51 | 13.53 |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 319.09 | -1.76 | 57.22 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
-56.04 | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
216.69 | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
-17.88 | - | - | $ 26.8 M | USA |
 |
Trean Insurance Group
TIG
|
-20.94 | - | - | $ 316 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
-139.05 | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
-170.94 | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
-125.3 | - | - | $ 13 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Lyra Therapeutics
LYRA
|
269.84 | - | - | $ 24.9 M | USA |
 |
Завод ДИОД
DIOD
|
3.1 | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-51.75 | - | - | - | Russia |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
-185.29 | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
-22.91 | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
-152.74 | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
88.41 | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
-33.23 | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
-68.38 | - | - | $ 2.36 B | USA |
 |
Exicure
XCUR
|
-125.98 | $ 1.09 | 3.81 % | $ 6.86 M | USA |
 |
Cellectis S.A.
CLLS
|
-89.05 | $ 0.95 | -3.3 % | $ 95.3 M |  France |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 12.03 | 1.78 % | $ 3.59 B | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-0.35 | $ 58.93 | 1.57 % | $ 7.88 B | USA |
 |
BioMarin Pharmaceutical
BMRN
|
5.73 | $ 55.62 | -0.59 % | $ 10.7 B | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 29.48 | 0.79 % | $ 1.96 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-188.93 | $ 3.75 | 2.18 % | $ 45.8 M |  Israel |
 |
Jaguar Health
JAGX
|
0.29 | $ 2.36 | 15.44 % | $ 5.5 M | USA |
 |
Protalix BioTherapeutics
PLX
|
-13.69 | $ 2.49 | -2.35 % | $ 196 M | Israel |
 |
uniQure N.V.
QURE
|
-100.05 | $ 21.65 | -3.5 % | $ 1.24 B | Niderland |
 |
Stoke Therapeutics
STOK
|
-1.95 | $ 25.41 | 1.48 % | $ 1.5 B | USA |
 |
Xencor
XNCR
|
-14.46 | $ 29.2 | 15.95 % | $ 2.17 B | USA |
 |
Annexon
ANNX
|
-97.66 | $ 3.71 | -1.2 % | $ 575 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 1.71 | -4.21 % | $ 2.82 M | Israel |
 |
Incyte Corporation
INCY
|
24.9 | $ 113.3 | -2.08 % | $ 22.1 B | USA |
 |
Mesoblast Limited
MESO
|
-17.1 | $ 12.43 | 1.22 % | $ 15 B |  Australia |
 |
MeiraGTx Holdings plc
MGTX
|
1971.36 | $ 9.2 | -0.16 % | $ 740 M | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
21.18 | $ 516.39 | -1.44 % | $ 132 B | USA |
 |
Burford Capital Limited
BUR
|
2.56 | $ 3.24 | -3.72 % | $ 710 M |  Britain |
 |
Catalyst Biosciences
CBIO
|
9.32 | $ 12.77 | -0.39 % | $ 1.14 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 25.47 | 1.29 % | $ 1.19 B | USA |
 |
Anika Therapeutics
ANIK
|
-7.58 | $ 21.19 | -1.07 % | $ 304 M | USA |
 |
Editas Medicine
EDIT
|
-586.56 | $ 2.4 | 0.05 % | $ 213 M | USA |
 |
Evogene Ltd.
EVGN
|
-65.36 | $ 0.37 | 0.44 % | $ 2.91 M | Israel |
 |
EyePoint Pharmaceuticals
EYPT
|
-75.78 | $ 0.36 | -10.09 % | $ 26.4 K | USA |
 |
Fortress Biotech
FBIO
|
74.19 | $ 1.87 | -3.11 % | $ 52.2 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-27461.1 | $ 10.12 | 0.4 % | $ 289 M | USA |
|
Foghorn Therapeutics
FHTX
|
68.46 | $ 2.04 | 2.0 % | $ 128 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
16.98 | $ 13.76 | 4.13 % | $ 11.5 B |  India |